Remdesivir (RDV) has demonstrated clinical benefit in hospitalized COronaVIrus Disease
(COVID)-19 patients. The objective of this brief report was to assess a possible correlation …

A significant proportion of COVID-19 patients will progress to critical illness requiring
invasive mechanical ventilation. This accentuates the need for a therapy that can reduce the …

Background:" COVID-19, 2019" orCoronavirus is an infections malady bring about by
acuterespiratory disorder" coronavirus 2SARS-CoV-2". The first case was diagnosed in …

Background Remdesivir (RDV) is an intravenous antiviral with activity against SARS-CoV-2
for treatment of hospitalized COVID-19 patients with moderate-to-severe disease …

Remdesivir is one of the most attractive options for patients with hypoxemic respiratory
failure due to coronavirus disease 2019 (COVID-19). The aim of our study was to evaluate …

The infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
generated many challenges to find an effective drug combination for hospitalized patients …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the
world causing a pandemic known as coronavirus disease 2019 (COVID-19). Cytokine storm …

Background Patients with haematological malignancies have an increased susceptibility for
COVID-19 and higher mortality. They may also have prolonged symptoms and viral …

Materials and Methods: We performed a systematic search in Pubmed, Embase, Web of
Science, Google scholar and MedRxiv for relevant observational and interventional studies …

The antiviral remdesivir has been shown to decrease the length of hospital stay in
coronavirus disease 2019 (COVID‐19) patients requiring supplemental oxygen. However …